IsoPlexis | Getting more from single cells
14869
home,page,page-id-14869,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,qode-theme-ver-5.3,wpb-js-composer js-comp-ver-4.3.4,vc_responsive
we get more from single cells

we get more from single cells

At IsoPlexis, we are helping researchers and clinicians discover how patients' immune systems respond to disease, at the molecular level. As therapies and illnesses have evolved, so has the need to measure and monitor patients' precise immune function.
That's where we come in.

a comprehensive definition of patient t-cell function

Big data meets cellular specificity for the first time. In-depth T-cell analysis requires both. This is how our technology helps determine if effective therapy responses have occurred and what they look like.

changing immunology with actionable information

We help researchers and clinicians apply our novel technologies to their toughest problems. We then work with them to translate the large amount of patient data, from the smallest of samples, into actionable patient solutions.

technology developed with leaders in the field

IsoPlexis employs advanced single-cell analytics originally spun out of Yale University and developed in concert with leading cancer and engineering centers. See below for publication details.

IN THE PRESS

Yale Startup IsoPlexis Raises $1.25M to Advance their Cell Decoding Micro-device

–

Yale bioscience tools company IsoPlexis recently closed on a $1.25 million Series A round with investments from Spring Mountain Capital, Connecticut Innovations and others. 
READ MORE
IN THE PRESS

Spring Mountain Capital, LP Leads Investment in IsoPlexis Corporation

–

Spring Mountain Capital, LP, a New York-based investment management firm, announced today that its private equity group structured and led a growth equity investment in IsoPlexis Corporation.
READ MORE
IN THE PRESS

New Microchip Technology Achieves 42-plexed Single-Cell Protein Analysis

–

A team of researchers at Yale University have invented a novel microdevice capable of detecting 42 unique immune effector proteins, a record number for a single-cell protein secretion assay.

READ MORE

our solution gives researchers and clinicians a comprehensive picture of patient immune cell response to therapies and disease

RECENT PNAS PUBLICATION
Highly Multiplexed Profiling of Single-Cell Effector Functions Reveals Deep Functional Heterogeneity in Response to Pathogenic Ligands
READ MORE
RECENT CANCER DISCOVERY PUBLICATION
JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
READ MORE